Abstract
Background and study aim: COVID-19 mortality, severity, and recovery are major global concerns, but they are still insufficiently understood, particularly in the Middle East. This retrospective study aimed to investigate the link between baseline clinical and laboratory data of COVID-19 patients and disease severity and mortality. Patients and Methods: A total of 180 adult Egyptian COVID-19 patients were compared according to their disease severity and mortality . Results: The Of all, 27.8% had severe disease, and 13.9% died during their hospital stay. Diabetes (46.7%), hypertension (36.1%), and chronic obstructive pulmonary disease (COPD) (33.3%) were the most frequent associated co-morbidities. Severe patients and non-survivors were significantly older compared to their corresponding groups. Their neutrophil count, PCT, ESR, CRP, AST, ALT, LDH, D-dimer, and ferritin levels were significantly higher (P ≤ 0.05). In contrast, their lymphocyte count was significantly lower (P ≤ 0.05). COPD (OR: 3.294; 95% CI: 1.199-9.053), diabetes (OR: 2.951; 95% CI:1.070-8.137), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551), AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991), CT-scoring system (CT-SS) ≥ 17 (OR: 1.205; 95% CI: 1.089-1.334) and lymphocyte count < 1×103/µL (OR: 4.002; 95% CI: 1.537-10.421), were all linked to higher COVID-19 severity. While mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359), CT-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482) and AST ≥ 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661). Conclusion: Clinical and laboratory data of COVID-19 patients at their hospital admission may aid in identifying early risk factors for severe illness and mortality rates .
Highlights
chronic obstructive pulmonary disease (COPD) (OR: 3.294; 95% confidence intervals (CI): 1.199-9.053), diabetes (OR: 2.951; 95% CI:1.0708.137), ferritin ≥ 350 ng/mL (OR: 11.08; 95% CI: 2.796-41.551), AST ≥ 40 IU/L (OR: 3.07; 95% CI: 1.842-7.991), CTscoring system (CT-SS) ≥ 17 (OR: 1.205; 95% CI: 1.089-1.334) and lymphocyte count < 1×103/μL (OR: 4.002; 95% CI: 1.537-10.421), were all linked to higher COVID-19 severity
While mortality was predicted by dyspnea (OR: 4.006; 95% CI: 1.045-15.359), computed tomography (CT)-SS ≥ 17 (OR: 1.271; 95% CI: 1.091-1.482) and AST ≥ 40 IU/L (OR: 2.89; 95% CI: 1.091-7.661)
Clinical and laboratory data of COVID-19 patients at their hospital admission may aid in identifying early risk factors for severe illness and mortality rates
Summary
Coronavirus disease 2019 (COVID19) is an extremely infectious illness caused by the SARS-CoV-2 coronavirus, which was originally established in Wuhan, China, in early December 2019. The first COVID-19 case in Egypt was reported in February 2020, and since the number of cases has been dramatically rising. COVID-19 infection is most commonly transmitted through respiratory droplets, as well as human-to-human contact [3]. It causes a wide range of symptoms that can. COVID-19 mortality, severity, and recovery are major global concerns, but they are still insufficiently understood, in the Middle East. This retrospective study aimed to investigate the link between baseline clinical and laboratory data of COVID-19 patients and disease severity and mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Afro-Egyptian Journal of Infectious and Endemic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
